Arch Biopartners Inc
XTSX:ARCH

Watchlist Manager
Arch Biopartners Inc Logo
Arch Biopartners Inc
XTSX:ARCH
Watchlist
Price: 1.86 CAD 3.91%
Market Cap: 120.6m CAD
Have any thoughts about
Arch Biopartners Inc?
Write Note

Arch Biopartners Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Arch Biopartners Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Arch Biopartners Inc
XTSX:ARCH
Cash from Operating Activities
-CA$2.7m
CAGR 3-Years
14%
CAGR 5-Years
-6%
CAGR 10-Years
-26%
Abcellera Biologics Inc
NASDAQ:ABCL
Cash from Operating Activities
-$43.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Replicel Life Sciences Inc
XTSX:RP
Cash from Operating Activities
-CA$2m
CAGR 3-Years
-16%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Innovotech Inc
XTSX:IOT
Cash from Operating Activities
-CA$43.9k
CAGR 3-Years
N/A
CAGR 5-Years
-13%
CAGR 10-Years
12%
No Stocks Found

Arch Biopartners Inc
Glance View

Market Cap
119.5m CAD
Industry
Life Sciences Tools & Services

Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.

ARCH Intrinsic Value
0.29 CAD
Overvaluation 84%
Intrinsic Value
Price

See Also

What is Arch Biopartners Inc's Cash from Operating Activities?
Cash from Operating Activities
-2.7m CAD

Based on the financial report for Jun 30, 2024, Arch Biopartners Inc's Cash from Operating Activities amounts to -2.7m CAD.

What is Arch Biopartners Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-26%

The average annual Cash from Operating Activities growth rates for Arch Biopartners Inc have been 14% over the past three years , -6% over the past five years , and -26% over the past ten years .

Back to Top